(Q34294223)

1 August 2017

1 reference

title

Novel clinical strategies for the treatment of pancreatic carcinoma (English)

1 reference

1 August 2017

W H Günzburg

1

1 reference

1 August 2017

B Salmons

series ordinal

2

1 reference

1 August 2017

publication date

1 January 2001

1 reference

Trends in Molecular Medicine

1 August 2017

published in

1 reference

1 August 2017

volume

7

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

30-37

1 reference

1 August 2017

cites work

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Topoisomerase I poisons and suppressors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF)

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Identification of proliferating dendritic cell precursors in mouse blood

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Heat shock protein--peptide complexes as immunotherapy for human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

The p53 tumour suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

p53 function and dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

p53-dependent cell death/apoptosis is required for a productive adenovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

p14ARF links the tumour suppressors RB and p53.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

ONYX-015: clinical data are encouraging

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

LH-RH analogue treatment in adenocarcinoma of the pancreas: a phase II study. Gruppo Ligure per lo Studio del Pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Matrix metalloproteinase inhibitors: applications in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2800%2901865-7

7 January 2021

10.1016/S1471-4914(00)01865-7

Identifiers

DOI

1 reference

1 August 2017

1 reference